Valuation: Astellas Pharma Inc.

Market Cap 4,031B 25.49B 22.77B 21.25B 19.3B 36.34B 2,465B 36.62B 255B 99.74B 1,254B 95.68B 93.61B P/E 2027 *
10.6x
P/E 2028 * 11.1x
Enterprise Value 3,972B 25.11B 22.44B 20.93B 19.01B 35.81B 2,429B 36.08B 252B 98.28B 1,235B 94.27B 92.24B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.62x
Free-Float
98.92%
Yield 2027 *
3.55%
Yield 2028 * 3.68%
1 day-0.33%
1 week-3.12%
Current month-3.12%
1 month-2.39%
3 months+3.38%
6 months-13.94%
Current year+7.41%
1 week 2,216
Extreme 2216
2,322
1 month 2,182.5
Extreme 2182.5
2,413
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 64 10/02/2023
Director of Finance/CFO 55 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 64 01/06/2019
Director/Board Member 59 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%-3.12%+35.26%+9.15% 25.57B
-2.55%+1.22%+37.63%+103.57% 1,060B
-1.08%-1.03%+34.95%+61.47% 623B
-0.67%+3.71%+16.58%+80.79% 480B
-1.19%-1.67%+63.66%+35.32% 352B
-1.11%+1.89%+22.07%+41.76% 345B
-1.35%+0.32%+11.21%+34.39% 274B
-1.33%-1.95%-5.79%+10.91% 249B
-1.67%-0.01%+38.22%+49.97% 223B
-0.35%-1.09%+23.37%+94.36% 182B
Average -1.09%-0.72%+27.72%+52.17% 381.36B
Weighted average by Cap. -1.42%+0.02%+30.14%+66.69%

Financials

2027 *2028 *
Net sales 2,347B 14.84B 13.26B 12.37B 11.23B 21.16B 1,435B 21.32B 149B 58.07B 730B 55.7B 54.5B 2,189B 13.84B 12.37B 11.54B 10.48B 19.74B 1,339B 19.89B 139B 54.18B 681B 51.97B 50.84B
Net income 367B 2.32B 2.07B 1.93B 1.76B 3.31B 224B 3.33B 23.23B 9.08B 114B 8.71B 8.52B 346B 2.19B 1.95B 1.82B 1.65B 3.12B 211B 3.14B 21.89B 8.55B 107B 8.2B 8.03B
Net Debt -59.18B -374M -334M -312M -283M -534M -36.2B -538M -3.75B -1.46B -18.41B -1.4B -1.37B -481B -3.04B -2.72B -2.53B -2.3B -4.33B -294B -4.37B -30.44B -11.89B -150B -11.41B -11.16B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
08/10/26 JPY 2,248.00 -0.33% 5,458,800
07/10/26 JPY 2,255.50 +0.53% 5,853,100
06/10/26 JPY 2,243.50 +0.38% 5,031,100
05/10/26 JPY 2,235.00 -0.45% 4,295,600
02/10/26 JPY 2,245.00 -2.83% 5,521,400
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,255.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+12.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock